OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Cost of Revenue

Last Annual Value

830.00K

3-Year CAGR

%

5-Year CAGR

86%

10-Year CAGR

36%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Cost of Revenue

OKUR · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
830.00K
N/A75.4%N/A 
0.00
N/AN/AN/A
897.00K
N/A-9.9%19.3%
930.00K
N/AN/AN/A
3.97M
0.1%51.4%72.1%
1.54M
N/A0.6%N/A
811.00K
N/A9.1%26.5%
0.00
N/AN/AN/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47